Open Access

[Corrigendum] Thymoquinone inhibits epithelial‑mesenchymal transition in prostate cancer cells by negatively regulating the TGF‑β/Smad2/3 signaling pathway

  • Authors:
    • Bo Kou
    • Wei Liu
    • Wei Zhao
    • Peng Duan
    • Yang Yang
    • Qiuyue Yi
    • Fengwei Guo
    • Jianpeng Li
    • Jinsong Zhou
    • Qingshan Kou
  • View Affiliations

  • Published online on: February 2, 2023     https://doi.org/10.3892/or.2023.8491
  • Article Number: 54
  • Copyright : © Kou et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

View Figures

Related Articles

Journal Cover

March-2023
Volume 49 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kou B, Liu W, Zhao W, Duan P, Yang Y, Yi Q, Guo F, Li J, Zhou J, Kou Q, Kou Q, et al: [Corrigendum] Thymoquinone inhibits epithelial‑mesenchymal transition in prostate cancer cells by negatively regulating the TGF‑β/Smad2/3 signaling pathway. Oncol Rep 49: 54, 2023
APA
Kou, B., Liu, W., Zhao, W., Duan, P., Yang, Y., Yi, Q. ... Kou, Q. (2023). [Corrigendum] Thymoquinone inhibits epithelial‑mesenchymal transition in prostate cancer cells by negatively regulating the TGF‑β/Smad2/3 signaling pathway. Oncology Reports, 49, 54. https://doi.org/10.3892/or.2023.8491
MLA
Kou, B., Liu, W., Zhao, W., Duan, P., Yang, Y., Yi, Q., Guo, F., Li, J., Zhou, J., Kou, Q."[Corrigendum] Thymoquinone inhibits epithelial‑mesenchymal transition in prostate cancer cells by negatively regulating the TGF‑β/Smad2/3 signaling pathway". Oncology Reports 49.3 (2023): 54.
Chicago
Kou, B., Liu, W., Zhao, W., Duan, P., Yang, Y., Yi, Q., Guo, F., Li, J., Zhou, J., Kou, Q."[Corrigendum] Thymoquinone inhibits epithelial‑mesenchymal transition in prostate cancer cells by negatively regulating the TGF‑β/Smad2/3 signaling pathway". Oncology Reports 49, no. 3 (2023): 54. https://doi.org/10.3892/or.2023.8491